[CAS NO. 5054-59-1] Thalidomide-4-OH
PRODUCTS SPECIFICATIONS [5054-59-1]
DESCRIPTION [5054-59-1]
Overview
| MDL | MFCD03699892 |
|---|---|
| Molecular Weight | 274.23 |
| Molecular Formula | C13H10N2O5 |
| SMILES | OC1=CC=CC(C(N2C3C(NC(CC3)=O)=O)=O)=C1C2=O |
Summary
IC50 & Target
|
Cereblon |
In Vitro
Thalidomide may exert anti-angiogenic effect in isolated blood vessels and endothelial cells. Thalidomide-OH is a putative hydroxylated thalidomide metabolite. Thalidomide-OH has weak anti-angiogenic activity (14% mean inhibition of blood vessel density at 100 mg). Thalidomide-OH does not have any anti-proliferative effect against the breast or neuroblastoma cells, but do possess appreciable anti-proliferative activity against the endothelial cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : ≥ 36.5 mg/mL ( 133.10 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.6466 mL | 18.2329 mL | 36.4657 mL |
| 5 mM | 0.7293 mL | 3.6466 mL | 7.2931 mL |
| 10 mM | 0.3647 mL | 1.8233 mL | 3.6466 mL |
